Losartan vs Amlodipine: Switching Between Them and Which One Is Right for You

What Is the Core Difference Between Losartan and Amlodipine?

Losartan blocks the angiotensin II type-1 receptor, reducing vasoconstriction and aldosterone secretion. Amlodipine blocks L-type calcium channels in vascular smooth muscle, producing direct vasodilation. These are entirely different molecular targets, which means the drugs complement rather than duplicate each other.

Mechanism and Pharmacokinetics

Losartan has a relatively short half-life of 6-9 hours, though its active metabolite EXP3174 extends duration to roughly 24 hours, permitting once-daily dosing at 25-100 mg. Renal elimination dominates, so dose adjustment is needed in severe hepatic impairment.

Amlodipine has one of the longest half-lives of any antihypertensive: 35-50 hours. That extended half-life means missed doses have less impact on 24-hour blood pressure control, and it also means side effects like edema can persist for days after discontinuation.

Blood-Pressure-Lowering Potency

Head-to-head data comparing losartan directly to amlodipine as monotherapies is limited. A meta-analysis published in the Journal of Human Hypertension (2002) pooled data from multiple ARB trials and found that amlodipine 10 mg generally produced slightly greater systolic reductions (roughly 2-3 mmHg) than losartan 50 mg at equivalent titration points, though the difference narrowed when losartan was titrated to 100 mg. Neither drug consistently dominates across all patient phenotypes.

Where the Guidelines Stand

The ACC/AHA 2017 hypertension guidelines designate both thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers as first-line agents for most adults [1]. The guidelines do not rank losartan above amlodipine or vice versa in uncomplicated hypertension; the choice is guided by comorbidities and tolerability.

What Does the LIFE Trial Tell Us About Losartan?

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial enrolled 9,193 patients with hypertension and electrocardiographic left ventricular hypertrophy (LVH) and compared losartan-based therapy to atenolol-based therapy over a mean follow-up of 4.8 years [2]. Losartan produced a 13% relative risk reduction in the composite primary endpoint of cardiovascular death, stroke, and myocardial infarction (P<0.021), driven largely by a 25% relative reduction in stroke (P<0.001).

What LIFE Did Not Prove

LIFE was not a losartan-versus-amlodipine trial. The comparator was atenolol, a beta-blocker now considered inferior for primary hypertension in most patients. Clinicians should not interpret LIFE as evidence that losartan outperforms calcium channel blockers; it outperformed a beta-blocker in a high-LVH population.

The LVH and Stroke Signal

The stroke reduction in LIFE was striking enough that the American Heart Association specifically acknowledges ARBs as preferred agents in patients with LVH [3]. If your patient has documented LVH on ECG or echo, losartan carries a specific evidence base that amlodipine does not replicate in the same population.

What Does ASCOT-BPLA Tell Us About Amlodipine?

The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) randomized 19,257 patients with hypertension and at least three additional cardiovascular risk factors to either an amlodipine-based regimen (with perindopril added if needed) or an atenolol-based regimen (with bendroflumethiazide added if needed) [4]. The trial was stopped early at 5.5 years because the amlodipine arm showed 23% fewer fatal and non-fatal strokes (P<0.0003) and 11% fewer major cardiovascular events (P = 0.0247).

What ASCOT Adds Beyond Stroke

ASCOT-BPLA also showed a 36% reduction in new-onset diabetes in the amlodipine-perindopril arm vs atenolol-thiazide (P<0.0001) [4]. This metabolic advantage has made amlodipine-based combinations attractive in patients at risk for type 2 diabetes, though the benefit was partly attributable to avoiding the metabolically unfavorable atenolol-thiazide combination rather than purely to amlodipine itself.

Interpretation for Practice

Like LIFE, ASCOT-BPLA compared an active treatment arm to atenolol, not to an ARB. The evidence base for amlodipine's superiority is specifically over beta-blocker-based regimens, not over losartan. Clinicians choosing between these two drugs are largely operating on mechanism, comorbidity mapping, and tolerability data rather than a definitive head-to-head trial.

How Do Side Effects Differ Between Losartan and Amlodipine?

Side-effect profiles are often the deciding factor when choosing between these agents or when a patient asks to switch.

Amlodipine Side Effects

Peripheral edema is the most clinically significant adverse effect of amlodipine. In the ALLHAT trial (N=33,357), the calcium channel blocker arm (chlorthalidone was the comparator, but amlodipine was the largest CCB subgroup studied) showed edema rates roughly twice those of the diuretic arm [5]. Package insert data for amlodipine places the edema rate at 10.8% for the 10 mg dose. The edema is due to precapillary vasodilation without a matched postcapillary effect; it does not represent volume overload or cardiac decompensation.

Flushing, headache, and reflex tachycardia are less common but do occur, especially at initiation. These effects tend to attenuate within 2-4 weeks as the body adapts to lower peripheral resistance.

Losartan Side Effects

Losartan's most clinically relevant risks are hyperkalemia and a rise in serum creatinine, both of which reflect its mechanism of blocking aldosterone secretion and reducing efferent arteriolar tone. In patients with CKD stage 3B or worse (eGFR <45 mL/min/1.73 m²), baseline labs and a recheck at 1-2 weeks after initiation are standard practice.

Losartan does not cause the dry cough that occurs with ACE inhibitors (bradykinin-mediated), which is why it is the preferred alternative for the roughly 10-15% of patients who develop ACE inhibitor cough [6]. Angioedema risk exists but is dramatically lower with ARBs than with ACE inhibitors; cross-reactivity angioedema from an ACE inhibitor to an ARB is estimated at <10% and most guidelines consider cautious ARB use acceptable in that scenario.

Side-Effect Comparison at a Glance

| Side Effect | Losartan | Amlodipine | |---|---|---| | Peripheral edema | Rare (<1%) | Up to 10.8% at 10 mg | | Hyperkalemia | Moderate risk (CKD, K⁺-sparing diuretics) | Not applicable | | Dry cough | Does not cause | Does not cause | | Flushing/headache | Rare | Common at initiation | | Angioedema | Rare | Not reported | | Reflex tachycardia | Not applicable | Mild, usually transient |

When Is Losartan the Better Choice?

Several clinical scenarios favor losartan over amlodipine based on guideline recommendations and trial data.

Diabetic Nephropathy and CKD with Proteinuria

The RENAAL trial (N=1,513) showed that losartan 100 mg daily reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% compared to placebo in patients with type 2 diabetes and nephropathy (P = 0.02) [7]. No comparable trial has established amlodipine as a renoprotective agent in proteinuric CKD. Current KDIGO guidelines recommend an ARB as first-line antihypertensive therapy in adults with CKD and albuminuria [8].

Left Ventricular Hypertrophy

The LIFE data outlined above make losartan the preferred ARB for patients with documented LVH, particularly those at elevated stroke risk. Regression of LVH was significantly greater with losartan than atenolol in LIFE, and LVH regression is independently associated with better cardiovascular outcomes.

ACE Inhibitor Intolerance

If a patient cannot tolerate lisinopril, enalapril, or another ACE inhibitor because of cough, switching to losartan preserves RAS blockade without the cough trigger. Amlodipine does not block RAS at all, so swapping ACE inhibitor for amlodipine loses the nephroprotective and cardiac remodeling benefits of RAS suppression.

When Is Amlodipine the Better Choice?

Isolated Systolic Hypertension in Older Adults

Systolic blood pressure is harder to control as large-artery compliance decreases with age. Calcium channel blockers perform particularly well in this population. The Systolic Hypertension in the Elderly Program (SHEP) used a diuretic-based approach, but subsequent data from ACCOMPLISH (N=11,506) showed that an amlodipine-benazepril combination reduced cardiovascular events by 20% compared to benazepril-hydrochlorothiazide (P<0.001), reinforcing amlodipine's utility in difficult-to-control systolic hypertension [9].

Angina and Vasospasm

Amlodipine carries an FDA indication for chronic stable angina and vasospastic (Prinzmetal) angina. Losartan has no approved indication for angina. A patient with both hypertension and angina is almost always better served by amlodipine as one of the antihypertensive agents.

Patients Who Cannot Tolerate Potassium Elevation

Any patient on a potassium-sparing diuretic (spironolactone, eplerenone, triamterene) or with a baseline serum potassium above 5.0 mEq/L warrants extra caution with ARBs. Amlodipine has no effect on potassium and is the safer default in that context.

How Do You Switch from Losartan to Amlodipine (or Vice Versa)?

Switching between these agents is straightforward in the majority of patients. Because they work through entirely different mechanisms and do not share pharmacodynamic interactions, cross-tapering is not required.

Switching from Losartan to Amlodipine

The standard approach is to stop losartan on day 1 and start amlodipine at 5 mg on the same day or the following morning. Amlodipine's 35-50 hour half-life means it takes 7-10 days to reach steady state, so patients may notice slightly higher blood pressure readings in the first week. Starting at 5 mg and titrating to 10 mg at 2-4 weeks if targets are not met is the typical protocol. Monitor blood pressure at 2 weeks and again at 4-6 weeks.

No rebound hypertension has been associated with stopping losartan abruptly. This distinguishes ARBs from beta-blockers, where abrupt cessation can cause rebound tachycardia and blood pressure surges.

Switching from Amlodipine to Losartan

Start losartan 50 mg on the day losartan is stopped, or the following day. Titrate to 100 mg after 4 weeks if systolic blood pressure remains above 130 mmHg (or the individualized target). Because amlodipine's half-life is so long, residual drug effect may persist for 3-5 days after the last dose, providing a pharmacological bridge. Check a basic metabolic panel (electrolytes, creatinine) at 2 weeks to confirm potassium and renal function are stable.

When to Split the Transition Over 1-2 Weeks

Patients with very labile blood pressure, those on multiple antihypertensives, or those with CKD may benefit from a slower transition. In those cases, some clinicians halve the amlodipine dose for 1 week while starting losartan at 25 mg, then complete the switch at week 2. This is a conservative approach with no dedicated trial data behind it, but it mirrors standard practice for complex hypertension management.

Post-Switch Monitoring Checklist

• Blood pressure at 7-14 days (the most important early check)
• Basic metabolic panel at 2 weeks when switching to losartan (potassium, creatinine)
• Assessment for new peripheral edema at 2-4 weeks when switching to amlodipine
• Medication adherence review at 6-week follow-up
• 24-hour ambulatory blood pressure monitoring if home readings are inconsistent

Can Losartan and Amlodipine Be Used Together?

Yes. Combining an ARB with a dihydropyridine CCB is one of the most evidence-supported two-drug combinations in hypertension management. The ACCOMPLISH trial (N=11,506) tested benazepril plus amlodipine vs benazepril plus hydrochlorothiazide and found the ARB/CCB combination reduced the primary composite endpoint by 20% (P<0.001) [9]. While ACCOMPLISH used benazepril rather than losartan, the principle extends to losartan: complementary mechanisms (RAS blockade plus calcium channel blockade) produce additive blood pressure reduction.

Fixed-dose combinations of amlodipine with an ARB are commercially available (e.g., olmesartan/amlodipine as Azor). A losartan/amlodipine fixed-dose combination is available in several countries outside the United States and is used widely in Asia and Europe.

Amlodipine's edema may actually be attenuated when combined with an ARB. RAS blockade increases postcapillary venodilation, partially counteracting the precapillary-dominant vasodilation that drives CCB-induced edema. This is a clinically meaningful benefit for patients who need amlodipine but cannot tolerate the edema as monotherapy.

Patient Profiles: Matching the Drug to the Person

Not every patient fits neatly into a trial cohort. The following profiles synthesize the evidence above into practical starting points.

Profile 1: 58-year-old with type 2 diabetes, eGFR 52, urine albumin-to-creatinine ratio 180 mg/g. Losartan 50-100 mg is the preferred agent. Renal protection is the primary goal, and RENAAL-level evidence supports ARB over CCB in this scenario.

Profile 2: 65-year-old with isolated systolic hypertension (160/78 mmHg), no diabetes, and a history of stable exertional angina. Amlodipine 5-10 mg addresses both the angina and the systolic hypertension. Adding an ARB later if targets are not met is a rational second step.

Profile 3: 47-year-old who stopped lisinopril due to persistent cough, eGFR 78, no diabetes. Losartan preserves RAS blockade without the cough. Amlodipine is an option but does not replace the mechanistic benefits of RAS suppression.

Profile 4: 72-year-old on spironolactone 25 mg for heart failure with preserved ejection fraction, serum K⁺ 5.1 mEq/L. Amlodipine is safer here. Adding losartan risks clinically significant hyperkalemia; the combination of an ARB and spironolactone requires very careful monitoring and is generally avoided unless there is a compelling indication.

What the Evidence Does Not Tell Us

No large, randomized trial has placed losartan directly against amlodipine in a head-to-head design with hard cardiovascular endpoints as the primary outcome. Both LIFE and ASCOT-BPLA used atenolol as the comparator, reflecting the era in which they were conducted. Inferring relative superiority of losartan over amlodipine, or the reverse, from those two trials is not methodologically valid.

The 2022 ACC/AHA Hypertension Guideline Update acknowledges this gap [10]. Current guidance recommends matching drug class to patient-specific factors rather than ranking first-line agents by efficacy alone.